Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | CNR1 | P21554 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CDK8 | P49336 | 1/20 | 0.52 |
| ▸ | PLAU | P00749 | 2/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | PLG | P00747 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4118285 | 0.93 | CA2 (0.64) | CA2CNR1MAPTMEN1KMT2A | |
| SCHEMBL4112018 | 0.88 | CA2 (0.70) | CA2CNR1MAPTMEN1KMT2A | |
| SCHEMBL4116278 | 0.87 | MAPT (0.56) | CA2POLBMAPTMEN1KMT2A | |
| SCHEMBL4104406 | 0.86 | CA2 (0.71) | CA2CNR1POLBMAPTMEN1 | |
| SCHEMBL4123557 | 0.85 | TP53 (0.72) | CA2CNR1MAPTMEN1KMT2A | |
| SCHEMBL4112132 | 0.84 | KMT2A (0.62) | CA2CNR1MAPTMEN1KMT2A | |
| SCHEMBL4105824 | 0.84 | CA2 (0.61) | CA2CNR1MAPTMEN1KMT2A | |
| SCHEMBL4115271 | 0.84 | CA2 (0.64) | CA2CNR1POLBMAPTMEN1 | |
| SCHEMBL12410421 | 0.83 | CA2 (0.63) | CA2CNR1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2093226 | 0.83 | CA2 (0.58) | CA2CNR1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | CNR1, CNR2, OPRL1 | CA2 4345/4885CNR1 1/4885POLB 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.